Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.38 |
| ▸ | WDR5 | P61964 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26171964 | 0.92 | GRM5 (0.36) | GRM5 | |
| SCHEMBL26003250 | 0.89 | LRRK2 (0.37) | LRRK2GRM5 | |
| SCHEMBL31312913 | 0.89 | LRRK2 (0.37) | LRRK2GRM5 | |
| SCHEMBL25339547 | 0.88 | NOTUM (0.44) | NPC1RAB9A | |
| SCHEMBL25339552 | 0.88 | NOTUM (0.44) | NPC1RAB9A | |
| SCHEMBL29021196 | 0.86 | ALDH1A1 (0.41) | GRM5 | |
| SCHEMBL24207014 | 0.85 | CHRM4 (0.38) | LRRK2 | |
| SCHEMBL31143335 | 0.85 | ACACB (0.37) | GRM5 | |
| SCHEMBL28899818 | 0.85 | LTA4H (0.39) | GRM5 | |
| SCHEMBL25957189 | 0.85 | LTA4H (0.39) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466262-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene, Ltd. (KY) | 2024-11-27 | — | — | EP | disclosed |
| US-20240368203-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2024-11-07 | — | — | US | disclosed |
| CN-118696038-A | EGFR degradation by conjugation of EGFR inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023138607-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE , LTD. (KY) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368203-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | MYC 526/4885WDR5 634/4885MCHR1 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.